Viewing Study NCT01005992


Ignite Creation Date: 2025-12-24 @ 3:51 PM
Ignite Modification Date: 2025-12-26 @ 2:00 AM
Study NCT ID: NCT01005992
Status: UNKNOWN
Last Update Posted: 2009-11-02
First Post: 2009-10-30
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Fractional Photothermolysis for the Treatment of Burn Scars
Sponsor: Clinica las Condes, Chile
Organization:

Study Overview

Official Title: Fractional Photothermolysis for the Treatment of Burn Scars
Status: UNKNOWN
Status Verified Date: 2009-10
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The aim of our study is to determine the effect of fractional photothermolysis laser in the treatment of burn scars.
Detailed Description: One of the main problems in the management of burned patients is the treatment of post-burn scarring. Frequently this scars cover large areas, tend to retract, present pigmentary changes and are disfiguring, producing significant life quality impairment.

Unfortunately, there are very few therapeutic options for treating these scars, which can be secondary to reconstructive surgery or after spontaneous healing. In the last decades most reports in scar treatment have included, pressure garments, chemical peeling, dermabrasion, ablative and non-ablative laser therapy and surgery with varying degrees of success. There is only one report treating burn scars with fractional laser, with good results.

The aim of our study is to determine the effect of of a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc.) in the treatment of burn scars.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: